Relief of measles-mumps-rubella vaccination pain using topical 4% amethocaine.
Published: 2004
Language: eng
Number of pages: 99
Description: The efficacy and safety of 4% amethocaine for reducing the pain of measles-mumps-rubella (MMR) vaccination was investigated in a double-blind, randomized placebo-controlled study.One hundred and twenty infants receiving their routine 12-month MMR vaccination were recruited and randomized to receive 1g of amethocaine or placebo 30 minutes prior to vaccination. The Modified Behavioural Pain Scale (MBPS) was the primary pain outcome measure. A blood sample was collected from infants 1 month post-vaccination to assess antibody titers. The amethocaine group (n = 61) had significantly lower pain scores than the placebo group (n = 59); 1.51 vs. 2.29 (p = 0.029). The rate of vaccination success (antibody titers considered protective against disease) was similar between treatment groups; 87% and 88% respectively (p = 0.823). Amethocaine 4% gel significantly reduced the pain associated with MMR vaccination in one year old infants when compared to placebo; development of protective antibody levels was not affected.
Notes: Adviser:  Gideon Koren.

Thesis (M.Sc.)--University of Toronto, 2004.

Electronic version licensed for access by U. of T. users.

Source: Masters Abstracts International, Volume: 42-06, page: 2179.

MICR copy on microfiche (2 microfiches).